title: Assessing the impact of safety monitoring on the efficacy analysis in large Phase III group sequential trials with non-trivial safety event rate.
abstract: In Phase III clinical trials for life-threatening conditions, some serious but expected adverse events, such as early deaths or congestive heart failure, are often treated as the secondary or co-primary endpoint, and are closely monitored by the Data and Safety Monitoring Committee (DSMC). A naïve group sequential design (GSD) for such a study is to specify univariate statistical boundaries for the efficacy and safety endpoints separately, and then implement the two boundaries during the study, even though the two endpoints are typically correlated. One problem with this naïve design, which has been noted in the statistical literature, is the potential loss of power. In this article, we develop an analytical tool to evaluate this negative impact for trials with non-trivial safety event rates, particularly when the safety monitoring is informal. Using a bivariate binary power function for the GSD with a random-effect component to account for subjective decision-making in safety monitoring, we demonstrate how, under common conditions, the power loss in the naïve design can be substantial. This tool may be helpful to entities such as the DSMCs when they wish to deviate from the prespecified stopping boundaries based on safety measures.
authors.affiliation: a Novartis Pharmaceuticals Corporation , East Hanover , New Jersey , USA.
authors.forename: Yanqiu
authors.initials: Y
authors.lastname: Weng
authors.affiliation: b Department of Public Health Sciences , Medical University of South Carolina , Charleston , South Carolina , USA.
authors.forename: Yuko Y
authors.initials: YY
authors.lastname: Palesch
authors.affiliation: c Division of Biostatistics , School of Public Health, University of Texas Health Sciences Center , Houston , Texas , USA.
authors.forename: Stacia M
authors.initials: SM
authors.lastname: DeSantis
authors.affiliation: b Department of Public Health Sciences , Medical University of South Carolina , Charleston , South Carolina , USA.
authors.forename: Wenle
authors.initials: W
authors.lastname: Zhao
mesh_terms: D001699:Biometry; D017326:Clinical Trials, Phase III as Topic; D003627:Data Interpretation, Statistical; D003657:Decision Making; D023381:Endpoint Determination; D006801:Humans; D012449:Safety
keywords: Data and safety monitoring committee; Type I error; efficacy; group sequential design; power; safety